The weight is over: Vivus confident as Qsymia launched for co-morbid obesity
This article was originally published in Scrip
Executive Summary
Vivus has launched Qsymia (phentermine and topiramate), the first new oral prescription weight loss drug in the US in 13 years, but CEO Leland Wilson isn't concerned about losing market share as competitors prepare to sell their own novel medications because of rising levels of obesity and associated cardiovascular and metabolic diseases.